Sandoz' Sandimmune for recalcitrant psoriasis
The immunosuppressive drug will be reviewed by FDA's Dermatologic Drugs Advisory Committee on Nov. 19. The committee will discuss Sandimmune (cyclosporine) in soft gelatin capsule and oral solutions (NDAs 50-695 and 50-696, respectively). Meeting is scheduled for the Holiday Inn Silver Spring Plaza (Plaza Ballroom), 8777 Georgia Ave., Silver Spring, Md. beginning at 9 a.m. The committee also will meet Nov. 20 in closed session to discuss pending INDs and NDAs.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth